N/A
N=169
Brief Treatment for Posttraumatic Stress Disorder
PTSD
Bottom Line
View on ClinicalTrials.gov: NCT03033602 ↗Enrolled (actual)
169
Serious AEs
1.2%
Results posted
May 2023
Primary outcome: Primary: Clinician Administered PTSD Scale, 5 (CAPS-5) — 31.55; 25.12; 29.59; 25.41 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- written exposure therapy (Behavioral); CPT, cognitive only (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boston VA Research Institute, Inc.
- Primary completion
- Dec 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinician Administered PTSD Scale, 5 (CAPS-5) |
31.55; 25.12; 29.59; 25.41; 27.77; 24.97 | — |
Summary
The primary goal of this study is to examine whether a brief treatment approach for PTSD is equally efficacious in the treatment of active duty service members relative to a first line treatment approach that requires much greater treatment dose.
Eligibility Criteria
Inclusion Criteria
- Male and female active duty military personnel who have deployed in support of a post-9/11 conflict seeking treatment for PTSD
- Diagnosis of PTSD
- Ability to speak, read and write English
- Not currently engaged in psychosocial treatment for PTSD
- Individuals taking psychotropic medications agree to work with their prescriber to remain on stable doses of any prescribed psychotropic medications for the duration of the intervention and through the first follow-up assessment as much as possible and as medically indicated.
Exclusion Criteria
- Current suicide or homicide risk meriting crisis intervention
- Active psychosis
- Moderate to severe brain damage
Data sourced from ClinicalTrials.gov (NCT03033602). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.